Privi Speciality Chemicals Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Strong top-line, margin normalization: Revenue grew +19.2% YoY on healthy demand, but gross margin compressed ~650 bps YoY as raw material costs normalized from an unusually favorable base. [Analyst stated 650 bps decline; management confirmed RMC percentage was higher but did not confirm the 650 bps figure.] EBITDA margin held near 25% on operating leverage.
• Capacity expansion is imminent: Phase-1 capacity (48k to 54k MT) commercializes within weeks, and Phase-2 (to 66k MT) is already underway, keeping the company on track for its ₹5,000 crore revenue vision in 3–4 years.
• The merger is a FY27 catalyst: The scheme to merge Privi Fine Sciences and Privi Biotechnologies has been filed with the NCLT, with completion expected this year, simplifying the corporate structure and consolidating capabilities.
• Bio-based technology is a post-5K story: A demonstration plant is being set up, but management was explicit that biomass contributions will not be material until after the ₹5,000 crore milestone, framing the next 2–3 years as a learning and scale-up phase.
• What to watch next quarter: Commercialization of the Phase-1 capacity, progress on the NCLT merger process, and whether the 20%+ EBITDA margin sustains as the product mix evolves with new capacity.

Revenue Growth & Demand Drivers

• Broad-based growth: The 19.22% YoY revenue increase was driven by a mix of volume, price increases, and improved product mix across both domestic and international markets.
• Structural demand intact: The fragrance and flavor value chain remained healthy despite global headwinds, supported by supply chain diversification, premiumization, and innovation trends that favor specialty aroma ingredients.
• Supply chain resilience: A diversified sourcing strategy, backward integration into pine chemistry, and a global procurement network provided stability through an evolving geopolitical environment.
• Volume disclosure declined: Management declined to provide a quarter-by-quarter breakup of volume growth versus realization, describing growth as "all-round" and committing to disclose volume data only at year-end.

Babani: "We are confident of achieving 20%, maintaining 20% CAGR with similar EBITDA margins. Means you can understand what I am trying to say. I do not want to speak numbers. What last year's number multiply by 20%, again, you multiply by 20%, that will be the minimum achieving that target."

Margin Walk & Cost Structure

• Gross margin compressed sharply: Gross margin fell ~650 bps YoY to 44.2% because Q1 last year benefited from low-cost raw material inventory and high selling prices during CY2025 contracts. Raw material cost as a percentage of sales normalized to the 52%–55% range.
• EBITDA margin held resilient: Despite the raw material headwind, EBITDA margin stayed at ~24.6%–25% as economies of scale reduced manufacturing and administrative expenses, and lower depreciation and interest costs protected PAT conversion.
• RMC range is structural: Management expects raw material cost to remain in the 52%–55% band on sales, with mix variations across over 75 products and ~60 raw materials causing a few percentage points of fluctuation quarter to quarter.
• Crude exposure is minimal: The Iran conflict had no significant impact on raw material costs because crude-based products are very limited in the portfolio; the company predominantly manufactures non-crude items.
• Camphor is immaterial: Camphor represents only 5%–6% of total revenue and is made from a CST route, unlike competitors who use volatile gum turpentine oil, insulating the company from that specific input cost volatility.

Narayan S. Iyer: "Anisha, the most important thing is that for us, camphor is one out of 75. For many others, it could be the product."

Capacity Expansion & the 5K/1K Roadmap

• Phase-1 imminent: The 6,000 MT capacity addition taking total installed capacity from 48,000 to 54,000 MT is expected to commercialize within ~15 days from the call date, a slight shift from the original June 2026 target to September 2026.
• Phase-2 underway: The balance 12,000 MT expansion to 66,000 MT has already commenced and is expected by September 2027, with Phase-3 CAPEX likely to begin around end of this year or early next year.
• New product platforms: Phase-2 and Phase-3 will introduce 10 advanced specialty products, and new plants for the furfural vertical, Musk T, and other specialty molecules are under implementation with mechanical completion expected by about middle of next year.
• Maltol competitive moat: The company will be the only one globally fully backward integrated from cob to Maltol and Ethyl Maltol, with plants designed to GMP standards for flavor-grade certification, giving it a substantial manufacturing cost advantage.
• Continuous flow chemistry push: The company is working to make all reactions continuous where possible, with upcoming large-scale molecules like Maltols starting with continuous manufacturing from day one, though specialty molecules obviously cannot be continuous.
• Funding discipline: CAPEX will be funded prima facie through internal accruals, with debt-to-EBITDA and debt-to-equity ratios closely monitored and kept well below thresholds; the current net debt-to-EBITDA stands at 1.29x.

Patil: "We always have believed and have proven that money lies within. So therefore, we continue to work every single day on improving the processes, reducing the steam cost and doing all of that."

Mergers, JVs & Strategic Alliances

• Merger filed with NCLT: The scheme of merger for Privi Speciality Chemicals Ltd, Privi Fine Sciences Pvt Ltd, and Privi Biotechnologies Pvt Ltd has been filed after receiving observation letters with no objection from both stock exchanges, with completion expected in this financial year.
• Privi Fine Sciences timeline: The merger is expected to complete by this year-end, bringing a different chemistry platform into the portfolio; backward integration for Fine Sciences may be considered once it becomes part of the Privi portfolio.
• PRIGIV JV scaling: The Givaudan JV achieved profitability in Q4 FY26 and delivered ₹18 crores revenue with 14%–15% EBITDA margin in Q1 FY27, with an additional ₹50 crore equity infusion agreed for the next expansion phase.
• Strategic alliances, not more JVs: Management disclosed two strategic alliances are underway but declined to provide scope or purpose, noting that joint ventures create conflicts when serving multiple customers and that alliances will be announced at the appropriate time.

Babani: "These are very, very tight ropes to walk on. We will have strategic alliances, but not joint ventures... one customer feels you are favoring the other."

Bio-Based Technology & Long-Term Bets

• Demonstration plant underway: A pilot plant in Navi Mumbai is being set up to handle 2 tons of biomass per day, currently processing a few hundred kilograms every fortnight, with multiple patents being filed.
• Post-5K story: Management was explicit that biomass is not part of the ₹5,000 crore roadmap; the demonstration plant will take 12–15 months to set up, then run for about a year to study manufacturing nuances before a large-scale plant is built, with contributions kicking in only after the 5K milestone.
• Breakthrough technologies in pipeline: Beyond biotechnology, management referenced other breakthrough technologies being worked on and said they will discuss them over the next 12 to 15 months, though no specifics were provided.

Babani: "In the Rs. 5,000 crore roadmap, this is nowhere part of the story. The part of the story will come future on after this Rs. 5,000 crores, the biomass projections will kick in. So, this will be first two, three years will be more learning, scale-up, doing homework for the future beyond 5K."

Guidance & Commitments

Key Metrics